{
  "id": "601c13b61cb411341a00000c",
  "type": "summary",
  "question": "What is LY-CoV555?",
  "ideal_answer": "LY-CoV555 is an anti-spike neutralizing antibody targeting the SARS-CoV-2 that has been tested for patients with Covid-19.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33113295",
    "http://www.ncbi.nlm.nih.gov/pubmed/33024963",
    "http://www.ncbi.nlm.nih.gov/pubmed/33215063"
  ],
  "snippets": [
    {
      "text": "SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33113295",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33024963",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "As of 8 August 2020, eight antibody candidates targeting the SARS-CoV-2\u00a0S protein have entered clinical studies, including LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, BRII-196, BRII-198 and SCTA01. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33215063",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33113295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33113295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33024963",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33024963",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}